MODERATE TO SEVERE PLAQUE PSORIASIS
Clinical trials for MODERATE TO SEVERE PLAQUE PSORIASIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE TO SEVERE PLAQUE PSORIASIS trials appear
Sign up with your email to follow new studies for MODERATE TO SEVERE PLAQUE PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Year Check-Up: how well does a common biologic drug work in everyday life?
Disease control CompletedThis study followed 127 adults for two years to see how well they stayed on a prescribed drug called secukinumab, which treats several related inflammatory conditions. Researchers tracked whether patients continued treatment and measured changes in their symptoms, pain, and quali…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New psoriasis drug shows promise for clearer skin
Disease control CompletedThis study tested a new medication called bimekizumab against an existing treatment, adalimumab, for adults with moderate to severe plaque psoriasis. It involved 478 participants and aimed to see which drug was better at clearing skin and improving symptoms. The study also monito…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New psoriasis drug begins human testing
Disease control CompletedThis early-stage study tested a new injection called SHR-1139 to see if it's safe for people. Researchers gave single doses to healthy volunteers and multiple doses to patients with moderate-to-severe plaque psoriasis. The main goal was to check for side effects and see how the d…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New psoriasis drug shows promise in Skin-Clearing trial
Disease control CompletedThis study tested whether an experimental drug called SCD-044 could safely reduce the skin plaques and symptoms of moderate to severe plaque psoriasis. It involved 263 adults who were randomly assigned to receive either the drug or a placebo for 16 weeks, with some continuing for…
Matched conditions: MODERATE TO SEVERE PLAQUE PSORIASIS
Phase: PHASE2 • Sponsor: Sun Pharmaceutical Industries Limited • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC